Watch the recorded webcast from Egetis’ Capital Markets Day

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment

Emcitate®

Our lead product candidate

Pipeline

General Corporate presentation

Press Releases

Regulatory

May 31, 2023

Board director in Egetis Therapeutics acquires shares

Read more

Regulatory

May 23, 2023

Egetis announces termination of discussions regarding a potential acquisition of the Company and provides a corporate update

Read more

Regulatory

April 27, 2023

Bulletin from Egetis Therapeutics’ Annual General Meeting 2023

Read more

Upcoming event

August 22, 2023

Interim report January-June 2023

Latest presentation

May 30, 2023

Nicklas Westerholm at ABGSC Life Science Summit

Latest Report

April 26, 2023

Q1 Report 2022

Calendar and upcoming reports

August 22, 2023

Interim report January-June 2023

November 8, 2023

Interim report January-September 2023

Joshua’s Story

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all